Nick joined Source BioScience in 2005 as CFO, becoming CEO in 2007. Nick oversaw the restructuring of the Group in 2006, determining and implementing the strategy to deliver the Group’s current activities. He has led the expansion of the Group through acquisitions and organic growth, investing in the technologies and expertise necessary to deliver the Group’s business plan, creating a profitable and cash generative business. Nick is a Chartered Accountant and holds a PhD in Mycology. Prior to joining Source BioScience, he was Finance Director at a regional airline and spent nine years with KPMG.

Dr Leaves joined the Group in 2007, becoming a Board member in 2008. Nick was a co-founder of Geneservice Limited in 2005 via a management buyout from the Medical Research Council. Prior to this, Nick worked for over ten years in complex genetics and genomics; first for Oxford University on asthma and eczema gene-hunting projects and then for the MRC in Cambridge on the mouse genome project. Nick qualified as a microbiologist and worked in the NHS completing a PhD in 1995 on the molecular methods used to characterise outbreaks of bacterial meningitis.

Mr Bakewell joined Source BioScience in 2005, becoming Finance Director in 2011 and being appointed to the Board in August 2012. Rob converted the Group to IFRS and has overseen the consolidation of the finance function and associated systems as the Group has expanded. Rob qualified as a Chartered Management Accountant in 1996 and has over ten years of regulatory compliance and corporate activity experience for listed companies. Prior to joining the Group he was Financial Controller at DCS Group plc which provided software solutions to global freight organisations and European motor retailers from
subsidiaries in Europe and the USA.

Mr Turnbull was appointed Chairman in 2006 and has extensive experience in a senior capacity in both public and private companies. Laurie has enjoyed a 30 year career as a CEO and senior executive. Former Chairman of the venture capital company Texas Group plc, where he was previously CEO for 15 years, he was responsible for numerous acquisitions and flotations. He has served on the boards of several listed companies in executive and non-executive capacities and has considerable experience in M&A.

Dr Foden joined the Board in 2003, bringing a background in venture capital, technology transfer and life sciences. Sue was an Investor Director with Merlin Biosciences from 2000 to 2003, following 13 years as CEO of Cancer Research Technology. Prior to that she was Head of Academic Liaison at Celltech Ltd. She is also a Non-Executive Director of Vectura plc, BerGenBio AS, Chair of Cizzle Biotech Ltd and of the seed fund Rainbow, and is an advisory board member for CD3. She has an MA and DPhil from the University of Oxford.